220 related articles for article (PubMed ID: 16115935)
1. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
Goffin J; Baral S; Tu D; Nomikos D; Seymour L
Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
[TBL] [Abstract][Full Text] [Related]
2. Phase II oncology trials: let's be positive.
Ratain MJ
Clin Cancer Res; 2005 Aug; 11(16):5661-2. PubMed ID: 16115898
[No Abstract] [Full Text] [Related]
3. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
4. Clinical drug development: an analysis of phase II trials, 1970-1985.
Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
7. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.
Bruno R; Claret L
Clin Pharmacol Ther; 2009 Aug; 86(2):136-8. PubMed ID: 19621009
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.
Gelmann EP
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-65-S1-70. PubMed ID: 9045318
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of renal cell carcinoma and malignant lymphoma. A causal relationship or coincidental occurrence?
Tihan T; Filippa DA
Cancer; 1996 Jun; 77(11):2325-31. PubMed ID: 8635103
[TBL] [Abstract][Full Text] [Related]
15. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
16. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
[TBL] [Abstract][Full Text] [Related]
17. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.
Yang BB; Kido A; Shibata A
Pharmacotherapy; 2007 Oct; 27(10):1387-93. PubMed ID: 17896894
[TBL] [Abstract][Full Text] [Related]
18. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and antiproliferative effects of an aqueous extract from the marine diatom Haslea ostrearia (Simonsen) against solid tumors: lung carcinoma (NSCLC-N6), kidney carcinoma (E39) and melanoma (M96) cell lines.
Carbonnelle D; Pondaven P; Morancais M; Masse G; Bosch S; Jacquot C; Briand G; Robert J; Roussakis C
Anticancer Res; 1999; 19(1A):621-4. PubMed ID: 10226609
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
